Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP885167.RA_YTeN2VDfw0BULYigAZzj7qxsOApo6-TjOqGfVnYB5I130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP885167.RA_YTeN2VDfw0BULYigAZzj7qxsOApo6-TjOqGfVnYB5I130_assertion type Assertion NP885167.RA_YTeN2VDfw0BULYigAZzj7qxsOApo6-TjOqGfVnYB5I130_head.
- NP885167.RA_YTeN2VDfw0BULYigAZzj7qxsOApo6-TjOqGfVnYB5I130_assertion description "[Interestingly, reducing ChREBP(OG) levels via OGA overexpression decreased lipogenic protein content (ACC, FAS), prevented hepatic steatosis, and improved the lipidic profile of OGA-treated db/db mice.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP885167.RA_YTeN2VDfw0BULYigAZzj7qxsOApo6-TjOqGfVnYB5I130_provenance.
- NP885167.RA_YTeN2VDfw0BULYigAZzj7qxsOApo6-TjOqGfVnYB5I130_assertion evidence source_evidence_literature NP885167.RA_YTeN2VDfw0BULYigAZzj7qxsOApo6-TjOqGfVnYB5I130_provenance.
- NP885167.RA_YTeN2VDfw0BULYigAZzj7qxsOApo6-TjOqGfVnYB5I130_assertion SIO_000772 21471514 NP885167.RA_YTeN2VDfw0BULYigAZzj7qxsOApo6-TjOqGfVnYB5I130_provenance.
- NP885167.RA_YTeN2VDfw0BULYigAZzj7qxsOApo6-TjOqGfVnYB5I130_assertion wasDerivedFrom befree-2016 NP885167.RA_YTeN2VDfw0BULYigAZzj7qxsOApo6-TjOqGfVnYB5I130_provenance.
- NP885167.RA_YTeN2VDfw0BULYigAZzj7qxsOApo6-TjOqGfVnYB5I130_assertion wasGeneratedBy ECO_0000203 NP885167.RA_YTeN2VDfw0BULYigAZzj7qxsOApo6-TjOqGfVnYB5I130_provenance.